American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: High-dose-rate brachytherapy

Akila Viswanathan, Sushil Beriwal, Jennifer F. De Los Santos, D. Jeffrey Demanes, David Gaffney, Jorgen Hansen, Ellen Jones, Christian Kirisits, Bruce Thomadsen, Beth Erickson

Research output: Contribution to journalArticle

Abstract

Purpose: This report presents an update to the American Brachytherapy Society (ABS) high-dose-rate (HDR) brachytherapy guidelines for locally advanced cervical cancer. Methods: Members of the ABS with expertise in cervical cancer formulated updated guidelines for HDR brachytherapy using tandem and ring, ovoids, cylinder, or interstitial applicators for locally advanced cervical cancer. These guidelines were written based on medical evidence in the literature and input of clinical experts in gynecologic brachytherapy. Results: The ABS affirms the essential curative role of tandem-based brachytherapy in the management of locally advanced cervical cancer. Proper applicator selection, insertion, and imaging are fundamental aspects of the procedure. Three-dimensional imaging with magnetic resonance or computed tomography or radiographic imaging may be used for treatment planning. Dosimetry must be performed after each insertion before treatment delivery. Applicator placement, dose specification, and dose fractionation must be documented, quality assurance measures must be performed, and followup information must be obtained. A variety of dose/fractionation schedules and methods for integrating brachytherapy with external-beam radiation exist. The recommended tumor dose in 2-Gray (Gy) per fraction radiobiologic equivalence (normalized therapy dose) is 80-90. Gy, depending on tumor size at the time of brachytherapy. Dose limits for normal tissues are discussed. Conclusion: These guidelines update those of 2000 and provide a comprehensive description of HDR cervical cancer brachytherapy in 2011.

Original languageEnglish (US)
Pages (from-to)47-52
Number of pages6
JournalBrachytherapy
Volume11
Issue number1
DOIs
StatePublished - Jan 2012
Externally publishedYes

Fingerprint

Brachytherapy
Cervix Uteri
Guidelines
Carcinoma
Uterine Cervical Neoplasms
Dose Fractionation
X Ray Tomography
Three-Dimensional Imaging
Neoplasms
Appointments and Schedules
Magnetic Resonance Spectroscopy
Therapeutics
Radiation

Keywords

  • Brachytherapy
  • Cervical cancer
  • High dose rate

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II : High-dose-rate brachytherapy. / Viswanathan, Akila; Beriwal, Sushil; De Los Santos, Jennifer F.; Demanes, D. Jeffrey; Gaffney, David; Hansen, Jorgen; Jones, Ellen; Kirisits, Christian; Thomadsen, Bruce; Erickson, Beth.

In: Brachytherapy, Vol. 11, No. 1, 01.2012, p. 47-52.

Research output: Contribution to journalArticle

Viswanathan, A, Beriwal, S, De Los Santos, JF, Demanes, DJ, Gaffney, D, Hansen, J, Jones, E, Kirisits, C, Thomadsen, B & Erickson, B 2012, 'American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: High-dose-rate brachytherapy', Brachytherapy, vol. 11, no. 1, pp. 47-52. https://doi.org/10.1016/j.brachy.2011.07.002
Viswanathan, Akila ; Beriwal, Sushil ; De Los Santos, Jennifer F. ; Demanes, D. Jeffrey ; Gaffney, David ; Hansen, Jorgen ; Jones, Ellen ; Kirisits, Christian ; Thomadsen, Bruce ; Erickson, Beth. / American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II : High-dose-rate brachytherapy. In: Brachytherapy. 2012 ; Vol. 11, No. 1. pp. 47-52.
@article{04df21da46244b3d9b11f1443dd655ef,
title = "American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: High-dose-rate brachytherapy",
abstract = "Purpose: This report presents an update to the American Brachytherapy Society (ABS) high-dose-rate (HDR) brachytherapy guidelines for locally advanced cervical cancer. Methods: Members of the ABS with expertise in cervical cancer formulated updated guidelines for HDR brachytherapy using tandem and ring, ovoids, cylinder, or interstitial applicators for locally advanced cervical cancer. These guidelines were written based on medical evidence in the literature and input of clinical experts in gynecologic brachytherapy. Results: The ABS affirms the essential curative role of tandem-based brachytherapy in the management of locally advanced cervical cancer. Proper applicator selection, insertion, and imaging are fundamental aspects of the procedure. Three-dimensional imaging with magnetic resonance or computed tomography or radiographic imaging may be used for treatment planning. Dosimetry must be performed after each insertion before treatment delivery. Applicator placement, dose specification, and dose fractionation must be documented, quality assurance measures must be performed, and followup information must be obtained. A variety of dose/fractionation schedules and methods for integrating brachytherapy with external-beam radiation exist. The recommended tumor dose in 2-Gray (Gy) per fraction radiobiologic equivalence (normalized therapy dose) is 80-90. Gy, depending on tumor size at the time of brachytherapy. Dose limits for normal tissues are discussed. Conclusion: These guidelines update those of 2000 and provide a comprehensive description of HDR cervical cancer brachytherapy in 2011.",
keywords = "Brachytherapy, Cervical cancer, High dose rate",
author = "Akila Viswanathan and Sushil Beriwal and {De Los Santos}, {Jennifer F.} and Demanes, {D. Jeffrey} and David Gaffney and Jorgen Hansen and Ellen Jones and Christian Kirisits and Bruce Thomadsen and Beth Erickson",
year = "2012",
month = "1",
doi = "10.1016/j.brachy.2011.07.002",
language = "English (US)",
volume = "11",
pages = "47--52",
journal = "Brachytherapy",
issn = "1538-4721",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II

T2 - High-dose-rate brachytherapy

AU - Viswanathan, Akila

AU - Beriwal, Sushil

AU - De Los Santos, Jennifer F.

AU - Demanes, D. Jeffrey

AU - Gaffney, David

AU - Hansen, Jorgen

AU - Jones, Ellen

AU - Kirisits, Christian

AU - Thomadsen, Bruce

AU - Erickson, Beth

PY - 2012/1

Y1 - 2012/1

N2 - Purpose: This report presents an update to the American Brachytherapy Society (ABS) high-dose-rate (HDR) brachytherapy guidelines for locally advanced cervical cancer. Methods: Members of the ABS with expertise in cervical cancer formulated updated guidelines for HDR brachytherapy using tandem and ring, ovoids, cylinder, or interstitial applicators for locally advanced cervical cancer. These guidelines were written based on medical evidence in the literature and input of clinical experts in gynecologic brachytherapy. Results: The ABS affirms the essential curative role of tandem-based brachytherapy in the management of locally advanced cervical cancer. Proper applicator selection, insertion, and imaging are fundamental aspects of the procedure. Three-dimensional imaging with magnetic resonance or computed tomography or radiographic imaging may be used for treatment planning. Dosimetry must be performed after each insertion before treatment delivery. Applicator placement, dose specification, and dose fractionation must be documented, quality assurance measures must be performed, and followup information must be obtained. A variety of dose/fractionation schedules and methods for integrating brachytherapy with external-beam radiation exist. The recommended tumor dose in 2-Gray (Gy) per fraction radiobiologic equivalence (normalized therapy dose) is 80-90. Gy, depending on tumor size at the time of brachytherapy. Dose limits for normal tissues are discussed. Conclusion: These guidelines update those of 2000 and provide a comprehensive description of HDR cervical cancer brachytherapy in 2011.

AB - Purpose: This report presents an update to the American Brachytherapy Society (ABS) high-dose-rate (HDR) brachytherapy guidelines for locally advanced cervical cancer. Methods: Members of the ABS with expertise in cervical cancer formulated updated guidelines for HDR brachytherapy using tandem and ring, ovoids, cylinder, or interstitial applicators for locally advanced cervical cancer. These guidelines were written based on medical evidence in the literature and input of clinical experts in gynecologic brachytherapy. Results: The ABS affirms the essential curative role of tandem-based brachytherapy in the management of locally advanced cervical cancer. Proper applicator selection, insertion, and imaging are fundamental aspects of the procedure. Three-dimensional imaging with magnetic resonance or computed tomography or radiographic imaging may be used for treatment planning. Dosimetry must be performed after each insertion before treatment delivery. Applicator placement, dose specification, and dose fractionation must be documented, quality assurance measures must be performed, and followup information must be obtained. A variety of dose/fractionation schedules and methods for integrating brachytherapy with external-beam radiation exist. The recommended tumor dose in 2-Gray (Gy) per fraction radiobiologic equivalence (normalized therapy dose) is 80-90. Gy, depending on tumor size at the time of brachytherapy. Dose limits for normal tissues are discussed. Conclusion: These guidelines update those of 2000 and provide a comprehensive description of HDR cervical cancer brachytherapy in 2011.

KW - Brachytherapy

KW - Cervical cancer

KW - High dose rate

UR - http://www.scopus.com/inward/record.url?scp=84856022087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856022087&partnerID=8YFLogxK

U2 - 10.1016/j.brachy.2011.07.002

DO - 10.1016/j.brachy.2011.07.002

M3 - Article

C2 - 22265437

AN - SCOPUS:84856022087

VL - 11

SP - 47

EP - 52

JO - Brachytherapy

JF - Brachytherapy

SN - 1538-4721

IS - 1

ER -